JPH0457648B2 - - Google Patents
Info
- Publication number
- JPH0457648B2 JPH0457648B2 JP24470690A JP24470690A JPH0457648B2 JP H0457648 B2 JPH0457648 B2 JP H0457648B2 JP 24470690 A JP24470690 A JP 24470690A JP 24470690 A JP24470690 A JP 24470690A JP H0457648 B2 JPH0457648 B2 JP H0457648B2
- Authority
- JP
- Japan
- Prior art keywords
- colostrum
- present
- hydroxyvitamin
- weight
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 210000003022 colostrum Anatomy 0.000 description 7
- 235000021277 colostrum Nutrition 0.000 description 7
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 For example Chemical compound 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- WFZKUWGUJVKMHC-UKBUZQLGSA-N calcitetrol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C WFZKUWGUJVKMHC-UKBUZQLGSA-N 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、1α−ヒドロキシビタミンD3類を含
有する血中脂質調節剤に関する。
近年、デルカ（De Luca）等及びコデイツク
（Kodiek）等の一連の研究の結果、ビタミンD3
の生体内活性物質が1α，25−ジヒドロキシビタ
ミンD3（以下1α，25−（OH）2−D3と略称する）で
あり、また1α位の水酸基の存在がその生物活性
の発現には必須であることが明らかにされた。以
後この活性型の1α，25−（OH）2−D3の類似体、
例えば1α−ヒドロキシビタミンD3（以下1α−
（OH）−D3と略称する）、1α，24−ジヒドロキシ
ビタミンD3（以下1α，24−（OH）2−D3と略称す
る）など多くの1α−ヒドロキシビタミンD3類が
合成され、1α，25−（OH）2−D3とともにそのビ
タミンＤ様生物活性が注目されており、1α−
（OH）−D3は慢性腎不全、副甲状腺機能低下症、
ビタミンＤ抵抗性クル病・骨軟化症におけるビタ
ミンＤ代謝異常を伴う諸症状（低カルシウム血
症、テタニー、骨痛、骨病変等）の改善に適応さ
れている。
本発明者等は、その後鋭意研究を続けた結果、
1α−ヒドロキシビタミンD3類に後述の血中脂質
調節作用のあることを見出し、本発明を完成し
た。
即ち本発明は、1α−ヒドロキシビタミンD3類
の血中脂質調節剤に関する。
本発明において用いられる1α−ヒドロキシビ
タミンD3類とは
1α−（OH）−D3，
1α，25−（OH）2−D3，
1α，24S−（OH）2−D3，
1α，24R−（OH）2−D3，
1α，24S，25−（OH）3−D3，
1α，24R，25−（OH）3−D3，
1α，25S，26−（OH）3−D3，
1α，25R，26−（OH）3−D3，
1α，25−（OH）2−23−OXO−D3，
1α，25−（OH）2−24−OXO−D3，
1α，25S，26−（OH）3−23−OXO−D3，
1α，25R，26−（OH）3−23−OXO−D3，
1α，25S−（OH）2−D3−26，23S−lactone，
1α，25R−（OH）2−D3−26，23S−lactone，
1α−（OH）−24，25，26，27−tetraucr−23−
COOH−C3
などが含まれる。
これらの本物質は例えばU.S.Patent 3697559，
特開昭51−76252、特開昭51−76254、U.S.
Patent3741996、特開昭55−22655、特開昭55−
22656、特開昭56−61351、Arch.Biochem.
Biophys.，204，387（1981），H.F.De Luca、ビ
タミンＤ−［その新しい流れ］、講談社、サイエン
テイフイク（1982）などに開示されている。
本発明においては光学異性体のいずれを用いて
もよく、又、二種以上を混合して用いてもよい。
本発明の血中脂質調節剤は活性成分として上記
本物質を含有して、下記に示す種々の製剤形態に
て用いられる。本発明の血中脂質調節剤は、経口
的、非経口的に投与される。
投与形態としては例えば、圧縮錠剤、被覆錠
剤、硬又は軟弾性ゼラチンカプセル、エチルアル
コール溶液、油性または水性溶液または懸濁液な
どが用いられる。
油性溶液の溶媒としては、植物油例えばヤシ
油、トウモロコシ油、綿実油、ココナツツ油、落
花生油、魚肝油、油状エステル例えばポリソルベ
ート80などを使用することができる。
直腸内投与の場合には坐剤ベース例えばカカオ
脂またはそのトリグリセライドなどを含む薬用組
成物とすることができる。
本物質は単位投与形態中、２×10-5乃至１×10
％、好ましくは２×10-4乃至１％を含有する。
又、投与量は0.1乃至104μｇ／日／人、好まし
くは0.5乃至103μｇ／／日／人とすすることがで
きる。そして、上記量的関係が保持されるよう
に、１日１〜３回の投与回数となるように調製さ
れる。
以下、実施例により本発明を詳述する。
実施例 １
血中脂質降下作用
日本白色種雄性ウサギ（体重2.5Kg）にコレス
テロール１％含有固形飼料（CR−１）を経口自
由摂取させ、約３ケ月後血清脂質成分の上昇を確
認して、これを実験的動脈硬化モデル動物として
使用した。
これら高脂血症を示すウサギは同時に粥状動脈
硬化を発症することがよく知られており、動脈硬
化モデル動物として従来より抗動脈硬化症剤の効
力検定に汎用されている。これらの動脈硬化モデ
ル動物に、MCTに溶解した本物質を1μｇ／Kg経
口投与した。投与後経時的に耳静脈より採血して
血清脂質分析を実施し、血液中の総コレステロー
ルの変化を酵素法により、又β−リポタンパクは
比濁法により測定した。
結果を下記表−１に示す。尚、結果は各群５匹
の平均値である。
The present invention relates to a blood lipid regulator containing 1α-hydroxyvitamin D3 . In recent years, as a result of a series of studies by De Luca et al. and Kodiek et al., vitamin D3
The active substance in the body is 1α,25-dihydroxyvitamin D 3 (hereinafter abbreviated as 1α,25-(OH) 2 -D 3 ), and the presence of a hydroxyl group at the 1α position is essential for the expression of its biological activity. It was revealed that. Hereafter analogs of this active form of 1α,25-(OH) 2 -D 3 ,
For example, 1α-hydroxyvitamin D 3 (hereinafter 1α-
(OH)-D 3 ), 1α,24-dihydroxyvitamin D 3 (hereinafter abbreviated as 1α,24-(OH) 2 -D 3 ), and many other 1α-hydroxyvitamin D 3 types have been synthesized. Along with 1α,25−(OH) 2 −D 3 , its vitamin D-like biological activity has attracted attention, and 1α−
(OH)-D 3 is chronic renal failure, hypoparathyroidism,
It is indicated for improving various symptoms associated with abnormal vitamin D metabolism (hypocalcemia, tetany, bone pain, bone lesions, etc.) in vitamin D-resistant rickets and osteomalacia. As a result of continued intensive research, the inventors found that
We have completed the present invention by discovering that 1α-hydroxyvitamin D 3 has a blood lipid regulating effect as described below. That is, the present invention relates to a blood lipid regulator of 1α-hydroxyvitamin D3 . The 1α-hydroxyvitamin D 3 used in the present invention is 1α-(OH)-D 3 , 1α, 25-(OH) 2 -D 3 , 1α, 24S-(OH) 2 -D 3 , 1α, 24R −(OH) 2 −D 3 , 1α, 24S, 25−(OH) 3 −D 3 , 1α, 24R, 25−(OH) 3 −D 3 , 1α, 25S, 26−(OH) 3 −D 3 , 1α, 25R, 26−(OH) 3 −D 3 , 1α, 25−(OH) 2 −23−OXO−D 3 , 1α, 25−(OH) 2 −24−OXO−D 3 , 1α, 25S ,26−(OH) 3 −23−OXO−D 3 , 1α,25R,26−(OH) 3 −23−OXO−D 3 , 1α,25S−(OH) 2 −D 3 −26,23S−lactone , 1α,25R−(OH) 2 −D 3 −26,23S−lactone, 1α−(OH)−24,25,26,27−tetraucr−23−
Includes COOH- C3 , etc. These substances are, for example, US Patent 3697559,
JP 51-76252, JP 51-76254, US
Patent3741996, JP-A-55-22655, JP-A-55-
22656, JP 56-61351, Arch.Biochem.
Biophys., 204 , 387 (1981), HFDe Luca, Vitamin D - [The New Trend], Kodansha, Scientific (1982), etc. In the present invention, any of the optical isomers may be used, or two or more types may be used as a mixture. The blood lipid regulator of the present invention contains the above substance as an active ingredient and is used in various formulations shown below. The blood lipid regulator of the present invention is administered orally or parenterally. Examples of dosage forms that can be used include compressed tablets, coated tablets, hard or soft elastic gelatin capsules, ethyl alcohol solutions, oily or aqueous solutions or suspensions. As solvents for oily solutions, vegetable oils such as coconut oil, corn oil, cottonseed oil, coconut oil, peanut oil, fish liver oil, oily esters such as polysorbate 80, etc. can be used. For rectal administration, the pharmaceutical composition may include a suppository base, such as cocoa butter or its triglycerides. The substance may be present in unit dosage form between 2 x 10 -5 and 1 x 10
%, preferably 2×10 −4 to 1%. The dosage may be 0.1 to 10 4 μg/day/person, preferably 0.5 to 10 3 μg/day/person. Then, in order to maintain the above-mentioned quantitative relationship, the dosage is adjusted to be administered 1 to 3 times a day. Hereinafter, the present invention will be explained in detail with reference to Examples. Example 1 Blood lipid lowering effect Japanese white male rabbits (body weight 2.5 kg) were given orally ad libitum solid feed containing 1% cholesterol (CR-1), and after about 3 months, an increase in serum lipid components was confirmed. This was used as an experimental arteriosclerosis model animal. It is well known that these hyperlipidemic rabbits also develop atherosclerosis, and have been widely used as arteriosclerosis model animals for testing the efficacy of anti-arteriosclerosis drugs. 1 μg/Kg of this substance dissolved in MCT was orally administered to these arteriosclerosis model animals. Blood was collected from the ear vein over time after administration, and serum lipid analysis was performed.Changes in total cholesterol in the blood were measured by an enzymatic method, and β-lipoprotein was measured by a turbidimetric method. The results are shown in Table 1 below. Note that the results are the average values of 5 animals in each group.
【表】
上述した本物質の毒物学的特性および薬理学的
特性からみて、本物質は抗動脈硬化症剤として実
用に供せられることが理解される。
実施例 ２
1α−（OH）−D3をパナセート800（日本油脂製、
中級脂肪酸のトリグリゼライド）に10μ／mlの濃
度に溶解し、１カプセル中に1α−（OH）−D3を1μ
ｇ含有するように下記剤皮成分を加温溶解し、軟
カプセル製造機を用いて常法により軟カプセル剤
を作成した。
剤皮処方例
ゼラチン 10重量部
グリセリン ２重量部
防腐剤（エチルパラベン） 0.05重量部
チタンホワイト 0.2重量部
水 0.2重量部
（最終形態に於ける重量部）
実施例 ３
実施例２の1α−（OH）−D3に代えて、1α，25
−（OH）2−D3を用い、以下同様にして1α，25−
（OH）2−D3を１カプセル当り1μｇを含有する軟
カプセル剤を得た。
実施例 ４
実施例２の1α−（OH）−D3に代えて、1α，24R
−（OH）2−D3を用い、以下同様にして1α，24R
−（OH）2−D3を１カプセル当り1μｇを含有する
軟カプセル剤を得た。[Table] In view of the above-mentioned toxicological and pharmacological properties of this substance, it is understood that this substance can be put to practical use as an anti-arteriosclerotic agent. Example 2 1α-(OH)-D 3 was added to Panacet 800 (NOF Co., Ltd.,
One capsule contains 1μ of 1α-(OH) -D3 dissolved in triglyceride (intermediate fatty acid) at a concentration of 10μ/ml.
The following shell components were heated and dissolved so as to contain 1.5 g, and soft capsules were prepared by a conventional method using a soft capsule making machine. Shell formulation example Gelatin 10 parts by weight Glycerin 2 parts by weight Preservative (ethylparaben) 0.05 parts by weight Titanium white 0.2 parts by weight Water 0.2 parts by weight (parts by weight in final form) Example 3 1α-(OH of Example 2) )−D 1α, 25 instead of 3
Using −(OH) 2 −D 3 , 1α, 25−
Soft capsules containing 1 μg of (OH) 2 -D 3 per capsule were obtained. Example 4 In place of 1α-(OH)-D 3 in Example 2, 1α,24R
Using −(OH) 2 −D 3 , 1α, 24R in the same manner
Soft capsules containing 1 μg of -(OH) 2 -D 3 per capsule were obtained.
１ カゼインを沈降させながら乳および／または
初乳を処理することによる乳および／または初乳
免疫グロブリン溶液の製造方法において、乳およ
び／または初乳を4.0〜5.5のPH値に酸性化し、平
均孔度0.1〜1.2μmの過装置を用いて第一次のク
ロスフロー過を行い、これから得られた液に
対して5000〜80000ダルトンの分離限界を有する
過装置を用いた第二次のクロスフロー過を行
つて低分子成分を除去することを特徴とする乳お
よび／または初乳免疫グロブリン溶液の製造方
法。
２ 出発物質として初乳を用いることを特徴とす
る特許請求の範囲第１項に記載の方法。
３ 出発物質として高度免疫化されていない哺乳
動物の初乳またはヒトの初乳を用いることを特徴
1. A method for producing milk and/or colostrum immunoglobulin solutions by treating milk and/or colostrum with precipitation of casein, in which the milk and/or colostrum is acidified to a PH value of 4.0 to 5.5 and the average pore A first cross-flow filtration is performed using a filtration device with a separation limit of 0.1-1.2 μm, and the resulting liquid is subjected to a second cross-flow filtration using a filtration device with a separation limit of 5000-80000 Daltons. 1. A method for producing a milk and/or colostrum immunoglobulin solution, which comprises removing low-molecular components by performing the following steps. 2. The method according to claim 1, characterized in that colostrum is used as a starting material. 3 Characterized by using colostrum of a non-hyperimmunized mammal or human colostrum as a starting material
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24470690A JPH03169820A (en) | 1983-08-02 | 1990-09-14 | Blood lipid regulating agent containing 1alpha-hydroxyvitamin d3 compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132383A JPS6045516A (en) | 1983-08-02 | 1983-08-02 | Physiologically active agent containing 1alpha- hydroxyvitamin d3 |
| JP24470690A JPH03169820A (en) | 1983-08-02 | 1990-09-14 | Blood lipid regulating agent containing 1alpha-hydroxyvitamin d3 compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14132383A Division JPS6045516A (en) | 1983-08-02 | 1983-08-02 | Physiologically active agent containing 1alpha- hydroxyvitamin d3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03169820A JPH03169820A (en) | 1991-07-23 |
| JPH0457648B2 true JPH0457648B2 (en) | 1992-09-14 |
Family
ID=26473577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24470690A Granted JPH03169820A (en) | 1983-08-02 | 1990-09-14 | Blood lipid regulating agent containing 1alpha-hydroxyvitamin d3 compounds |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03169820A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849729A (en) * | 1995-12-26 | 1998-12-15 | Hershey Foods Corporation | Use of hydrolyzed cocoa butter for percutaneous absorption |
-
1990
- 1990-09-14 JP JP24470690A patent/JPH03169820A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03169820A (en) | 1991-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5656667A (en) | Fatty acid composition | |
| US7652068B2 (en) | Omega 3 fatty acid formulations | |
| DE69114498T2 (en) | SHORT-BED, SIMPLY UNSATURATED FATTY ACIDS, AND PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS. | |
| JPH07502491A (en) | Use of emulsions to prepare intravenously administered drugs for the treatment of skin diseases | |
| FR2645441A1 (en) | TREATMENT OF HYPERPARATHYROIDIA THROUGH THE USE OF DERIVATIVES OF VITAMIN D | |
| US20130213851A1 (en) | Omega 3 fatty acid formulations | |
| DE3438821A1 (en) | USE OF 24.25-DIHYDROXYCHOLECALCIFEROL | |
| EP0734723A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| CH644518A5 (en) | PHARMACEUTICAL PREPARATION FOR REGULATING BONE METABOLISM. | |
| Koskelo et al. | High levels of dietary arachidonic acid triglyceride exhibit no subchronic toxicity in rats | |
| JPH0710761A (en) | Suppressor for reduction in bone weight in renal osteodystrophia | |
| JPH0319207B2 (en) | ||
| JPH0457648B2 (en) | ||
| GB2195890A (en) | Improving palatability of pharmaceutical chewable tablets | |
| JPS60120812A (en) | Remedy for diabetic osteopenia | |
| JPH0319209B2 (en) | ||
| JPH054367B2 (en) | ||
| JPH054368B2 (en) | ||
| JPH03169819A (en) | Antithrombotic agent containing 1alpha-hydroxyvitamin d3 compounds | |
| JPH069406A (en) | Antirachitic agent | |
| JPH08208464A (en) | Treatment and prevention drug for hyperlipidemia | |
| JPS6221330B2 (en) | ||
| US5571802A (en) | Method of treating post menopausal osteoporosis with hexafluro-vitamin D | |
| JPS6221333B2 (en) | ||
| JPH05294834A (en) | Active vitamin D-containing therapeutic agent |